Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication

Journal of the Indian Medical Association

Volumn 101, Issue 9, 2003, Pages 561-564

  Samra, Shivpreet S ^a   Bajaj, Parina ^b   Vijayaraghavan, K S ^c   Potdar, Nandkishor P ^d   Vyas, Dipak ^e   Devan, Ravi G ^f   Ballary, Chetna ^g   Desai, Anish ^g  

^a St George's Hospital   (India)

^b B J MEDICAL COLLEGE   (India)

^c SRI RAMACHANDRA UNIVERSITY   (India)

^d BOMBAY HOSPITAL   (India)

^e Lions Club Tarachandbapa Hospital   (India)

^f M R MEDICAL COLLEGE   (India)

^g Glenmark Pharmaceuticals Limited   (India)

Author keywords

Arterial occlusive disease; Cilostazol; Intermittent claudication; Peripheral arterial disease; Phosphodiesterase inhibitor; Platelet aggregation inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CILOSTAZOL; DICLOFENAC; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOXSUPRINE; NICOTINIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTOXIFYLLINE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOPPLER FLOWMETRY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; TREADMILL; WALKING; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 4544301103     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Schmeider FA, Comerota AJ - Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001; 87: 3D-13D.
2. Beebe HG - Intermittent claudication: effective management of a common circulatory problem. Am J Cardiol 2001; 87: 14D-18D.
3. Brook RD, Weder AB, Grossman PM, Rajagopalan S - Management of intermittent claudication. Cardiol Clin 2002; 20: 521-34.
4. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr - Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-86.
5. Reilly MP, Mohler ER 3rd - Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35: 48-56.
6. Smith JA - Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. Clin Cardiol 2002; 25: 91-4.
7. Hiatt WR - Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
8. Money SR, Herd JA, Isaacsohn JL, et al - Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267-75.
9. Beebe HG, Dawson DL, Cutler BS, et al - A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-50.
10. Thompson PD, Zimet R, Forbes WB, Zhang P - Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314-9.
11. Dawson DL, Cutler BS, Hiatt WR, et al - A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-30.
12. Carson SN - Adjunctive therapy for ischemic wounds using cilostazol. Wounds 2003; 15: 77-82.
13. Gotoh F, Tohgi H, Hirai S, et al - Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.
14. Madias JE - Cilostazol: an "intermittent claudication" remedy for the management of third-degree AV block. Chest 2003; 123: 979-82.
15. Cariski AT - Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Pract Suppl 2001; 119: 11-8.
16. Elam MB, Heckman J, Crouse JR, et al - Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998; 18: 1942-7.
17. Ikewaki K, Mochizuki K, Iwasaki M, et al - Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass, LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. Metabolism 2002; 51: 1348-54.